指南与共识消化系统肿瘤

已切除胆道癌的辅助治疗:ASCO临床实践指南

Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
指南 / 共识 · J Clin Oncol · 2019-03-11

ASCO召集专家小组对已切除胆道癌辅助治疗文献进行系统综述,纳入3项III期随机对照试验、1项II期试验和16项回顾性研究,推荐已切除胆道癌患者接受6个月卡培他滨辅助化疗;对肝外胆管癌或胆囊癌且切缘镜下阳性(R1切除)患者可考虑放化疗,并推荐共同决策。

要点

  • 已切除胆道癌患者应接受6个月卡培他滨辅助化疗(基于III期随机对照试验证据)。
  • 肝外胆管癌或胆囊癌伴R1切除患者可考虑放化疗。
  • 推荐共同决策,权衡肝外胆管癌或胆囊癌患者放疗的风险与潜在获益。

核心结论

  • 基于III期随机对照试验证据,已切除胆道癌患者应接受6个月卡培他滨辅助化疗。
  • 肝外胆管癌或胆囊癌伴R1切除患者可考虑放化疗,并推荐共同决策以权衡放疗风险与获益。

研究设计与样本

  • ASCO召集专家小组,对已切除胆道癌辅助治疗文献进行系统综述,纳入3项III期随机对照试验、1项II期试验和16项回顾性研究。

主要发现

  • 系统综述纳入3项III期随机对照试验、1项II期试验和16项回顾性研究。
  • 基于一项III期随机对照试验的证据,已切除胆道癌患者应接受6个月卡培他滨辅助化疗。
  • 肝外胆管癌或胆囊癌伴R1切除患者可考虑放化疗。
  • 推荐共同决策,考虑肝外胆管癌或胆囊癌患者放疗相关的风险与潜在获益。

关键数值与推荐

  • 已切除胆道癌患者应接受6个月卡培他滨辅助化疗;该试验所用剂量见限定声明,卡培他滨剂量也可由机构和区域实践决定。
  • 肝外胆管癌或胆囊癌伴R1切除患者可考虑放化疗。
  • 推荐共同决策,考虑肝外胆管癌或胆囊癌患者放疗相关的风险与潜在获益。

临床怎么用

  • 已切除胆道癌患者应接受6个月卡培他滨辅助化疗。
  • 肝外胆管癌或胆囊癌伴R1切除患者可考虑放化疗。
  • 推荐共同决策,权衡肝外胆管癌或胆囊癌患者放疗的风险与潜在获益。
  • 卡培他滨剂量见限定声明,也可由机构和区域实践决定。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with resected biliary tract cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on adjuvant therapy for resected biliary tract cancer and provide recommended care options for this patient population. RESULTS: Three phase III randomized controlled trials, one phase II trial, and 16 retrospective studies met the inclusion criteria. RECOMMENDATIONS: Based on evidence from a phase III randomized controlled trial, patients with resected biliary tract cancer should be offered adjuvant capecitabine chemotherapy for a duration of 6 months. The dosing used in this trial is described in the qualifying statements, while it should be noted that the dose of capecitabine may also be determined by institutional and regional practices. Patients with extrahepatic cholangiocarcinoma or gallbladder cancer and a microscopically positive surgical resection margin (R1 resection) may be offered chemoradiation therapy. A shared decision-making approach is recommended, considering the risk of harm and potential for benefit associated with radiation therapy for patients with extrahepatic cholangiocarcinoma or gallbladder cancer. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Shroff RT, Kennedy EB, Bachini M, et al. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019. PMID: 30856044. doi:10.1200/JCO.18.02178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。